2,0
9. Okt. 2011
Aktueller Mitarbeiter
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Excellent pipeline that has a lot of potential. The oncology, RA, and biotech portfolios are really making inroads and will have a significant impact on patient treatment.
Kontras
Constant downsizing & restructuring leaves you always wondering when you'll be next to go. Pfizer still seems unprepared for Lipitor patent cliff.